Filing Flows › Protalix BioTherapeutics (PLX) › Recalls, complaints & regulation

Protalix BioTherapeutics (PLX): clinical trials

Protalix BioTherapeutics (PLX) beyond its filings: 1 active clinical trial.

Protalix BioTherapeutics' latest quarter

Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Protalix BioTherapeutics have?

1 active study on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.